Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)

Details for Australian Patent Application No. 2008320823 (hide)

Owner Novartis AG

Inventors Cong, Feng; Rangwala, Shamina M.; Ettenberg, Seth; Guth, Sabine

Agent Davies Collison Cave

Pub. Number AU-A-2008320823

PCT Pub. Number WO2009/056634

Priority 60/984,827 02.11.07 US

Filing date 31 October 2008

Wipo publication date 7 May 2009

International Classifications

A61K 39/395 (2006.01) Medicinal preparations containing antigens or antibodies - Antibodies

A61P 35/00 (2006.01) Antineoplastic agents

C07K 16/28 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Event Publications

15 April 2010 PCT application entered the National Phase

  PCT publication WO2009/056634 Priority application(s): WO2009/056634

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008320837-Frame and chip offset for SRNC in UE involved relocation on carrier sharing

2008320822-Biomarker for the prediction of responsiveness to an anti-tumour necrosis factor alpha (TNF) treatment